AR046310A1 - Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas. - Google Patents

Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas.

Info

Publication number
AR046310A1
AR046310A1 ARP040103898A ARP040103898A AR046310A1 AR 046310 A1 AR046310 A1 AR 046310A1 AR P040103898 A ARP040103898 A AR P040103898A AR P040103898 A ARP040103898 A AR P040103898A AR 046310 A1 AR046310 A1 AR 046310A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
heteroaryl
amino
group
Prior art date
Application number
ARP040103898A
Other languages
English (en)
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34658262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046310(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/861,219 external-priority patent/US7151089B2/en
Priority claimed from US10/861,090 external-priority patent/US7202223B2/en
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of AR046310A1 publication Critical patent/AR046310A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente se refiere a composiciones farmacéuticas que las contienen. Reivindicación 1: Un compuesto de fórmula (1), caracterizado porque Y se selecciona entre el grupo que consiste en una unión, -CH2- u -O-; cada uno de W, W1, y W2 se selecciona independientemente entre el grupo que consiste en hidrógeno y una prodroga aceptable para uso farmacéutico; y T se selecciona entre el grupo que consiste en: a) -C:::C-R, donde R se selecciona entre el grupo que consiste en i) tri[alquil(C1- 4)]sililo, -C(O)NR1R2, alcoxialquilo, heteroarilo, y heteroarilo sustituido, y fenilo sustituido con entre 1 y 3 sustituyentes que se seleccionan entre el grupo que consiste en alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, alcoxi, alcoxi sustituido, acilo, acilamino, aciloxi, aminoacilo, amidino, amino, amino sustituido, carboxilo, éster carboxílico, ciano, cicloalquilo, cicloalquilo sustituido, cicloalcoxi, cicloalcoxi sustituido, guanidino, halo, heteroarilo, heteroarilo sustituido, hidrazino, hidroxilo, nitro, tiol, y -S(O)mR3; donde R1 y R2 se seleccionan independientemente entre el grupo que consiste en hidrógeno, alquilo, alquilo sustituido, amino, amino sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico y heterocíclico sustituido siempre y cuando solamente uno de R1 y R2 sea amino o amino sustituido, y además donde R1 y R2, junto con el átomo de nitrógeno al que están unidos, forman un heterociclo o un heterociclo sustituido; R3 se selecciona entre el grupo que consiste en alquilo, alquilo sustituido, amino, amino sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico y heterocíclico sustituido; y m es un entero igual a 0, 1 ó 2; ii) -C(O)OR14, donde R14 es hidrógeno, alquilo o alquilo sustituido; b) -CH=CH-Q2, donde Q2 se selecciona entre hidrógeno o cis-metoxi; c) -C(O)H; d) -CH=NNHR15, donde R15 es H o alquilo; e) -CH=N(OR15), donde R15 es según se definió antes; f) -CH(OR16)2, donde R16 es alquilo (C3-6) y g) -B(OR15)2, donde R15 es según se definió antes; y sales o sales parciales de los mismos aceptables para uso farmacéutico.
ARP040103898A 2003-10-27 2004-10-26 Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas. AR046310A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51515303P 2003-10-27 2003-10-27
US10/861,219 US7151089B2 (en) 2003-10-27 2004-06-04 Nucleoside compounds for treating viral infections
US10/861,311 US7144868B2 (en) 2003-10-27 2004-06-04 Nucleoside compounds for treating viral infections
US10/861,090 US7202223B2 (en) 2003-10-27 2004-06-04 Nucleoside compounds for treating viral infections
US60281504P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
AR046310A1 true AR046310A1 (es) 2005-11-30

Family

ID=34658262

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103898A AR046310A1 (es) 2003-10-27 2004-10-26 Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas.

Country Status (10)

Country Link
US (2) US7244713B2 (es)
EP (1) EP1687321A1 (es)
JP (1) JP2007509943A (es)
AR (1) AR046310A1 (es)
AU (1) AU2004295291A1 (es)
CA (1) CA2543090A1 (es)
IL (1) IL174684A0 (es)
NZ (1) NZ546201A (es)
SV (1) SV2005001919A (es)
WO (1) WO2005054268A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
CA2543090A1 (en) * 2003-10-27 2005-06-16 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
EP1951724B1 (en) * 2005-11-17 2011-04-27 OSI Pharmaceuticals, Inc. FUSED BICYCLIC mTOR INHIBITORS
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
WO2009117482A1 (en) * 2008-03-19 2009-09-24 Osi Pharmaceuticals, Inc Mtor inhibitor salt forms
US8809344B2 (en) 2008-10-29 2014-08-19 Apath, Llc Compounds, compositions, and methods for control of hepatitis C viral infections
US8853373B2 (en) * 2009-08-14 2014-10-07 Hitachi, Ltd. Method and reagent for gene sequence analysis

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140851A (en) * 1977-11-21 1979-02-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides
JPS61229897A (ja) 1985-04-05 1986-10-14 Nippon Zoki Pharmaceut Co Ltd 新規ヌクレオシド化合物
US6211158B1 (en) * 1987-04-10 2001-04-03 Roche Diagnostics Gmbh Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US4968686A (en) * 1988-04-08 1990-11-06 The Regents Of The University Of Michigan Acyclic pyrrolo [2,3-d]pyrimidine analogs as antiviral agents
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
US5824796A (en) * 1988-09-28 1998-10-20 Epoch Pharmaceuticals, Inc. Cross-linking oligonucleotides
US5763597A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
EP0604409B1 (en) 1990-01-11 2004-07-14 Isis Pharmaceuticals, Inc. Oligonucleotide analogs for detecting and modulating rna activity and gene expression
US5681941A (en) * 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
EP0684953A4 (en) 1993-02-03 1999-12-22 Gensia Inc ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES.
AU6632094A (en) 1993-04-19 1994-11-08 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
EP0719274A1 (en) 1993-09-17 1996-07-03 Gilead Sciences, Inc. Method for dosing therapeutic compounds
US6150510A (en) * 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US6004939A (en) * 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
US6054442A (en) * 1995-07-06 2000-04-25 Board Of Regents, University Of Texas System Methods and compositions for modulation and inhibition of telomerase in vitro
FR2750435B1 (fr) 1996-06-27 1998-08-28 Appligene Oncor Procede de formation de complexes d'hybridation dont la stabilite depend peu de la composition en base des deux molecules d'acides nucleiques hybridees
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
EP1138689A1 (en) 2000-03-28 2001-10-04 Roche Diagnostics GmbH N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1539188B1 (en) * 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
CA2470521A1 (en) * 2001-12-21 2003-07-10 Micrologix Biotech Inc. Anti-viral 7-deaza l-nucleosides
WO2003062256A1 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2003209045B2 (en) * 2002-02-13 2006-12-14 Isis Pharmaceuticals, Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
AU2003237249A1 (en) * 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
US20040014108A1 (en) * 2002-05-24 2004-01-22 Eldrup Anne B. Oligonucleotides having modified nucleoside units
AU2003269902A1 (en) 2002-07-16 2004-02-02 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003254657A1 (en) 2002-07-25 2004-02-16 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
WO2004028481A2 (en) 2002-09-30 2004-04-08 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
WO2004044140A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceticals, Inc. 2’-substituted oligomeric compounds and compositions for use in gene modulations
US7151089B2 (en) * 2003-10-27 2006-12-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CA2543090A1 (en) * 2003-10-27 2005-06-16 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
US7244713B2 (en) 2007-07-17
US20050215511A1 (en) 2005-09-29
WO2005054268A1 (en) 2005-06-16
EP1687321A1 (en) 2006-08-09
IL174684A0 (en) 2006-08-20
NZ546201A (en) 2009-05-31
AU2004295291A1 (en) 2005-06-16
US20070167383A1 (en) 2007-07-19
CA2543090A1 (en) 2005-06-16
SV2005001919A (es) 2005-08-18
JP2007509943A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
AR046310A1 (es) Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas.
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR055041A1 (es) Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
CO5300399A1 (es) Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
PE20030865A1 (es) Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c
CY1108445T1 (el) Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
AR081653A1 (es) Inhibidores del virus de la hepatitis c
AR064319A1 (es) Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros
AR074862A1 (es) Derivados de heterociclo biciclicos y sus metodos de uso
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
RU2009141613A (ru) 5-членное гетероциклическое соединение и его применение для лекарственных целей
CO5611128A2 (es) Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales
BR0114986A (pt) Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida.
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
ATE538780T1 (de) Medizinische zusammensetzung, enthaltend ein hmg- coa reduktase inhibitor und ein aminoalkohol derivat, als immunsuppressivum
AR036093A1 (es) Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета

Legal Events

Date Code Title Description
FB Suspension of granting procedure